0001609550-26-000023
SEC filingQ1 revenue grew modestly 1.6% to $204.6M amid reimbursement uncertainty, with gross margin expanding to 86.5% from favorable product mix, though net loss of $11.3M emerged from tax volatility while cash flow turned positive at $12.8M.
Revenue reached $204.6 million in Q1 FY2026, up 1.6% from $201.3 million in the prior year quarter. This modest growth occurred despite recent coding and reimbursement decisions that adversely impacted results, with management anticipating continued pressure on 2026 revenue due to uncertainty and volatility from multiple stakeholders. The resilience reflects underlying demand for Inspire therapy systems amid these headwinds.
Operating income showed progress, narrowing the loss to -$1.1 million from -$1.5 million, a 24.7% reduction. While specific expense details are limited, research and development costs benefited from internal reallocations to SG&A and cost of goods sold, partially offset by rises in sourcing and clinical studies. These dynamics demonstrate cost discipline supporting scalability as revenue grows.
Net income swung to a $11.3 million loss from a $3.0 million profit, reflecting volatility in other income and tax effects. Other income, net declined due to lower interest and dividend income from reduced average rates and cash balances. This shift highlights sensitivity to non-operating factors, though core operations remain the focus.